WaveMan
WaveMan · Company
NAMS · Newamsterdam Pharma Co N.V.
> Search tickers & screens ⌘K
LIVE
← All companies

NAMS NewAmsterdam Pharma (NAMS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001936258
Quote by TradingView
C-suite buying · 1Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
117
13F, latest reported quarter
Conversions, 180 days
7
Codes C/M, not in net · $2.3M priced

What the filings say about NAMS

Insiders, 180 days
-$7.8M net sold
1 buyer · 3 sellers · 12% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$3.5M
1 notice

NewAmsterdam Pharma insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, NewAmsterdam Pharma Co N.V. insiders sold a net $7.8M of stock across 115 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Kastelein Johannes Jacob Pieter
Chief Scientific Officer
SELL
2026-10-02 SECtraded 2026-09-30
50,246
$1.3M
-13.6%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Mar 9, 2026.
  • The trade is 72.5% of the 69,302 shares held after it.
  • 1 other insider sold within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Kastelein Johannes Jacob Pieter sold about $1.3M of NAMS under a 10b5-1 plan on Sep 30, 2026; 1 other insider sold within 30 days and 117 funds added in the latest 13F quarter.
Davidson Michael H.
Chief Executive Officer
BUY
2026-09-15 SECtraded 2026-09-14
10,000
$226.5K
-6.9%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (2 buys, 8 sales), the last on Mar 2, 2026.
  • +22.3% median (+22.3% mean) 90-day return after 2 previous buys.
  • The trade is 1.3% of the 792,923 shares held after it.
  • No other insider bought within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Davidson Michael H. bought about $226.5K of NAMS on Sep 14, 2026, the largest insider purchase at the company on our record; 117 funds added in the latest 13F quarter.
Smither John W
Director
SELL
2026-09-09 SECtraded 2026-09-04
1,600
$40.5K
-9.8%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 18.3% of the 8,760 shares held after it.
  • 1 other insider sold within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Smither John W sold about $40.5K of NAMS on Sep 4, 2026; 1 other insider sold within 30 days and 117 funds added in the latest 13F quarter.
Kooij Louise Frederika
Chief Accounting Officer
SELL
2026-07-22 SECtraded 2026-07-20
70,200
$2.1M
-35.5%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (19 sales), the last on Jun 22, 2026.
  • The trade is 118.7% of the 59,153 shares held after it.
  • No other insider sold within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Kooij Louise Frederika sold about $2.1M of NAMS on Jul 20, 2026; 117 funds added in the latest 13F quarter.
Kooij Louise Frederika
Chief Accounting Officer
SELL
2026-07-22 SECtraded 2026-07-20
31,885
$990.0K
-35.5%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (19 sales), the last on Jun 22, 2026.
  • The trade is 116.9% of the 27,268 shares held after it.
  • No other insider sold within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Kooij Louise Frederika sold about $990.0K of NAMS on Jul 20, 2026; 117 funds added in the latest 13F quarter.
115 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 110 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$7.8M over 180 days
-$1.1M over 90 days
below 82% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
117 funds bought in last quarter
more than 75% of Pharma & Biotech
Revenue
-50.6% year over year
below 80% of Pharma & Biotech
Margin
-905.7% net margin
below 85% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
23.4% of the float short (float per yahoo 2026-10-26) · 9.4 days to cover · settled 2026-09-30
more than 87% of Pharma & Biotech
What changed in the last 30 days
Oct 2Chief Scientific Officer Kastelein Johannes Jacob Pieter sold $1.3M under a 10b5-1 plan (Sep 30)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.

Watch NAMS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-43.7%12M
-44%-23%-2%+18%2025-102025-122026-022026-042026-062026-082026-10 2026-03-02 · Davidson Michael H. sold $14.8M2026-02-26 · Davidson Michael H. sold $5.6M2026-03-05 · Kastelein Johannes Jacob Pieter sold $3.2M2026-03-09 · Kastelein Johannes Jacob Pieter sold $3.1M2026-03-06 · Kastelein Johannes Jacob Pieter sold $2.9M2025-12-23 · Kooij Louise Frederika sold $2.7M2026-05-26 · Kooij Louise Frederika sold $2.3M2026-02-24 · Davidson Michael H. sold $2.2M2026-07-20 · Kooij Louise Frederika sold $2.1M2026-02-25 · Davidson Michael H. sold $1.6M2025-12-26 · Kooij Louise Frederika sold $1.5M2026-03-11 · LANGE LOUIS G sold $1.3M2026-01-27 · Kooij Louise Frederika sold $1.3M2026-01-20 · Somaiya Mayur Ian sold $1.3M2026-09-30 · Kastelein Johannes Jacob Pieter sold $1.3M2026-06-22 · Kooij Louise Frederika sold $1.2M2026-01-26 · Kooij Louise Frederika sold $1.1M2026-02-20 · Kastelein Johannes Jacob Pieter sold $1.1M2026-01-28 · Kooij Louise Frederika sold $1.0M2026-07-20 · Kooij Louise Frederika sold $990.0K2025-12-24 · Kooij Louise Frederika sold $928.1K2026-01-23 · Kooij Louise Frederika sold $849.5K2026-03-06 · LANGE LOUIS G sold $829.0K2026-01-21 · Somaiya Mayur Ian sold $823.4K2026-01-20 · Somaiya Mayur Ian sold $634.8K2026-02-26 · Davidson Michael H. sold $617.3K2026-02-20 · Kastelein Johannes Jacob Pieter sold $514.2K2026-01-21 · Somaiya Mayur Ian sold $512.8K2026-01-23 · Kooij Louise Frederika sold $438.8K2026-02-25 · Davidson Michael H. sold $375.3K2026-09-14 · Davidson Michael H. bought $226.5K2026-01-05 · Kastelein Johannes Jacob Pieter sold $199.5K2026-01-05 · Somaiya Mayur Ian sold $170.2K2026-02-24 · Davidson Michael H. sold $115.3K2026-07-20 · Kooij Louise Frederika sold $92.4K2026-01-05 · Kooij Louise Frederika sold $88.0K2026-02-25 · Davidson Michael H. sold $47.7K2026-09-04 · Smither John W sold $40.5K2026-01-20 · Somaiya Mayur Ian sold $27.6K2026-03-11 · LANGE LOUIS G sold $13.9K2026-01-26 · Kooij Louise Frederika sold $10.3K2026-06-22 · Kooij Louise Frederika sold $9.2K2026-08-24 · Kastelein Johannes Jacob Pieter filed to sell $3.5M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NAMS: institutional holders (13F)

13F holdings, latest reported quarter
Frazier Life Sciences Management, L.P.
18,589,235 sh
$623.7M
Capital World Investors
12,230,557 sh
$414.5M
FMR LLC
10,339,663 sh
$350.4M
RA CAPITAL MANAGEMENT, L.P.
9,883,524 sh
$330.8M
FCPM III SERVICES B.V.
8,490,353 sh
$287.7M

Congress trades in NAMS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NAMS planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Kastelein Johannes Jacob Pieter
Filed 2026-08-24
$3.5M

NAMS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALPS Medical Breakthroughs ETF
$4.0M position · as of 2026-05-31
2.5%
AlphaCentric Life Sciences and Healthcare Fund
$503.9K position · as of 2026-06-30
1.1%
Global X Guru Index ETF
$543.2K position · as of 2026-07-31
0.9%
Knights of Columbus Small Cap Equity Fund
$1.1M position · as of 2026-07-31
0.5%
Empower Small Cap Growth Fund
$1.3M position · as of 2026-06-30
0.5%
Kennedy Capital ESG SMID Cap Fund
$474.6K position · as of 2026-06-30
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$13.6M
$30.5M
$4.3M
+222%
+35%
2024
$6.5M
$49.5M
$2.6M
+136%
+4%
2023
$5.8M
$4.7M
$3.3M
+2%
+5%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $7.8M sold by insiders over 180 days, 117 funds added last quarter, $3.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

NAMS financials

Revenue growth
-50.6%
XBRL, annual
Net margin
-905.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$7.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-3,633%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$143.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-36.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-34.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-34.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-6.1%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$22.5M$45.6M$14.1M$102.7M
Operating income-$225.7M-$176.3M-$183.0M-$3.6M
Net income-$203.0M-$242.0M-$177.0M-$22.6M
EPS (diluted)-1.72-2.56-2.15-1.19
Operating cash flow-$147.8M-$158.6M-$141.2M$10.7M
Cash$490.0M$771.7M$340.4Mn/a
SEC XBRL, fiscal years, as known on 2026-10-27

NAMS Stock Sonar score 5/7 axes

Find similar shapesCompare

NAMS ranks highest on institutional and government (75th percentile) and profitability (62nd), and lowest on growth (20th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
62
Inputs
  • Return on equity-36.7% · 63 pct, sector of 545
  • Return on assets-34.0% · 57 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-34.7% · 65 pct, sector of 576
Growth
20
Inputs
  • Revenue growth, YoY-50.6% · 20 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
37
Inputs
  • Net Form 4 buying (codes P and S), 180d-$6.5M · 17 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
75
Inputs
  • Funds adding, latest quarter117 · 75 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
39
Inputs
  • Short interest, % of float+23.4% · 10 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+7.5% · 67 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NAMS filings, in plain words

Are NewAmsterdam Pharma insiders buying or selling NAMS?

In the 180 days to 2026-10-27, NewAmsterdam Pharma insiders were net sellers, a net $7.8M: $226.5K of purchases and $8.0M of sales reported on Form 4, by 1 buyer and 3 sellers.

Are there planned insider sales of NAMS?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $3.5M of stock; the latest, by Kastelein Johannes Jacob Pieter, was filed 2026-08-24.

Read the full summary

In the 180 days to 2026-10-27, NewAmsterdam Pharma insiders were net sellers of NAMS, a net $7.8M across purchases and sales reported on Form 4 by 1 buyer and 3 sellers. Sales outweighed purchases more than tenfold by value. 12% of the 8 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $3.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies